LOW-LEVEL VIREMIA IN CHRONIC HEPATITIS B PATIENTS RECEIVING TENOFOVIR OR ENTECAVIR

被引：0
|
作者：
Adilijiang, Munire [1 ]
Zhang, Yongping [1 ]
机构：
[1] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Infect Dis, Urumqi, Xinjiang, Peoples R China
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1112
引用
收藏
页码：S243 / S244
页数：2
相关论文
共 50 条
  • [1] Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide
    Wang, Xiaohao
    Cai, Dachuan
    Juan, Zhang
    JOURNAL OF HEPATOLOGY, 2022, 77 : S878 - S878
  • [2] Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study
    Chen, He
    Fu, Juan-Juan
    Li, Li
    Wang, Xia
    Pan, Xiu-Cheng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (01) : 180 - 184
  • [3] Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
    Lee, Seung Bum
    Jeong, Joonho
    Park, Jae Ho
    Jung, Seok Won
    Jeong, In Du
    Bang, Sung-Jo
    Shin, Jung Woo
    Park, Bo Ryung
    Park, Eun Ji
    Park, Neung Hwa
    CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (03) : 364 - 375
  • [4] Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia
    Li, Zhong-Bin
    Li, Le
    Niu, Xiao-Xia
    Chen, Song-Hai
    Fu, Yi-Ming
    Wang, Chun-Yan
    Liu, Yan
    Shao, Qing
    Chen, Guofeng
    Ji, Dong
    LIVER INTERNATIONAL, 2021, 41 (06) : 1254 - 1264
  • [5] Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment
    Li, Zhong-Bin
    Chen, Dan-Dan
    Jia, Yun-Fei
    He, Qing-Juan
    Cui, Li
    Du, Feng-Xia
    Kang, Yao-Jie
    Feng, Xin
    He, Mengwen
    Jin, Xue-Yuan
    Chen, Jing
    Wang, Yudong
    Ji, Dong
    Lau, George
    Wu, Shu-Gao
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [6] Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia
    刘丽萍
    ChinaMedicalAbstracts(InternalMedicine), 2023, 40 (02) : 84 - 85
  • [7] TENOFOVIR ALAFENAMIDE FOR THE TREATMENT OF CHRONIC HEPATITIS B PATIENTS WITH LOW-LEVEL VIREMIA: A PROSPECTIVE REAL-WORLD STUDY
    Ji, Dong
    Li, Zhong-Bin
    Wang, Chun-Yan
    Li, Le
    Liu, Yan
    Chen, Guofeng
    HEPATOLOGY, 2021, 74 : 499A - 499A
  • [8] Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia
    Sanai, Faisal M.
    Aljawad, Mohammed
    Alghamdi, Abdullah Saeed
    Yehoshua, Alon
    Khathlan, Abdullah
    Alghamdi, Mohammed
    Kozma, Sam
    Smith, Nathaniel
    El-Moustaid, Fadoua
    Jeyakumar, Sushanth
    Kachru, Nandita
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2024, 30 (01): : 23 - 29
  • [9] LONG-TERM HEALTH AND ECONOMIC BENEFITS OF SWITCHING TO TENOFOVIR ALAFENAMIDE VERSUS CONTINUING ON ENTECAVIR IN CHRONIC HEPATITIS B PATIENTS WITH LOW-LEVEL VIREMIA IN SAUDI ARABIA
    Sanai, F.
    Aljawad, M.
    Alghamdi, A. S.
    Khathlan, A.
    Alghamdi, M.
    Kozma, S.
    Smith, N.
    El Moustaid, F.
    Jeyakumar, S.
    Kachru, N.
    VALUE IN HEALTH, 2022, 25 (12) : S171 - S172
  • [10] Low-Level Viremia and the Increased Risk of Hepatocellular Carcinoma in Patients Receiving Entecavir Treatment
    Kim, Jung Hee
    Sinn, Dong Hyun
    Kang, Wonseok
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    HEPATOLOGY, 2017, 66 (02) : 335 - 343
12345